ArticleCureus2023
Antimicrobial Effects of Platelet-Rich Plasma and Platelet-Rich Fibrin: A Scoping Review.
Article in Cureus, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. Cited by 24 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
24 citing papers in PubMed, 2 syntheses or guidelines pooled it, 20 citations in OpenAlex.
- Efficacy and safety of allogeneic platelet-rich plasma in chronic wound treatment: a meta-analysis of randomized controlled trials.Scientific reports · 2024Pooled it
- The Use of Platelet-Rich Fibrin (PRF) in the Management of Dry Socket: A Systematic Review.International journal of molecular sciences · 2024Pooled it
- Exploration of the Therapeutic Protocols and Underlying Molecular Mechanisms of Autologous Platelet-Rich Plasma in the Treatment of Deep Second-Degree Burns.Journal of cosmetic dermatology · 2026Trial
- Differential Therapeutic Efficacy of Autologous Platelet-Rich Plasma at Varying Concentrations in the Treatment of Deep Second-Degree Burn and Its Underlying Molecular Mechanisms.Journal of cosmetic dermatology · 2026Trial
- Using injectable Platelet-Rich fibrin to improve recovery after impacted lower third molar extraction: a randomized controlled clinical trial.Clinical oral investigations · 2025Trial
- The role of nanofat membranes in inhibiting bacterial growth: An in vitro analysis.JPRAS open · 2026Article
- Culture medium influences detectability of antimicrobial effects of autologous platelet concentrates against anaerobic periodontal pathogens.BMC oral health · 2026Article
- Antibacterial Activity of Fresh and Autoclaved Platelet-Rich Fibrin on Pseudomonas aeruginosa: An In Vitro Study.Journal of clinical laboratory analysis · 2026Article
- In Vitro Antimicrobial Potential of Different Platelet Concentrates Against Eight Clinically Relevant Oral Pathobionts.Antibiotics (Basel, Switzerland) · 2026Article
- Platelet-Rich Plasma for Postherpetic Neuralgia: Proposed Mechanisms, Clinical Evidence, and Future Research Directions.Journal of pain research · 2026Review
- A comprehensive evaluation of the antimicrobial efficacy of concentrated growth factor against biofilms associated with endodontic diseases: An in vitro study.Journal of clinical and experimental dentistry · 2026Review
- Platelet-rich therapies in cutaneous and mucocutaneous disorders characterized by inflammatory tissue responses: mechanistic insights and clinical evidence.Frontiers in medicine · 2026Review
- Clinical Evaluation of Autologous PRP (Platelet-Rich Plasma) in the Treatment of Periodontitis in Small-Breed Dogs.Animals : an open access journal from MDPI · 2025Article
- Dual-Action Regenerative Therapies: Regeneration and Antimicrobial Effects of Platelet- and Marrow-Derived Biologics.Biomedicines · 2025Review
- Bioengineered Skin from a Platelet-Derived Hydrogel Repairs Full Thickness Wounds in a Pre-Clinical Mouse Model.International journal of molecular sciences · 2025Article
- Review
- Stability of BTI Devices for Plasma Rich in Growth Factors (PRGF) Eye Drop Delivery Under Varying Storage and Handling Conditions.Biomedicines · 2025Article
- A new protocol (THIS and FAT) for the treatment of filler-induced vascular occlusion: a case series.Frontiers in medicine · 2025Article
- Autologous Growth Factor-Rich Concentrate (GFC) Injection in Non-union of Fractures: A Quasi-experimental Study.Indian journal of orthopaedics · 2024Article
- First- vs. Second-Generation Autologous Platelet Concentrates and Their Implications for Wound Healing: Differences in Proteome and Secretome.Bioengineering (Basel, Switzerland) · 2024Article
Corrections and comments
- Erratum issued
Authors and funding
6 authors at 4 institutions in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Platelet-rich plasma (PRP), derived from the centrifugation and subsequent separation of whole blood, results in an unusually high concentration of platelets. A newer form of platelet concentrate, platelet-rich fibrin (PRF), has also been developed. There has been significant research into the therapeutic effects of PRP, particularly in enhancing wound healing and preventing infections in surgical wounds. This scoping review aims to thoroughly evaluate preclinical and clinical evidence regarding the antimicrobial effects of PRP and PRF. In conducting this review, 612 records were examined, and 36 articles were selected for inclusion. The studies reviewed include preclinical research, such as in-vitro and in-vivo studies, and clinical trials involving human participants. The current clinical evidence suggests a notable trend towards the antimicrobial capabilities of PRP and PRF, underscoring their potential benefits in treating wounds. The application of PRP and PRF in wound management shows encouraging outcomes, but further investigation is needed to optimize their use as antimicrobial agents. Additional research, particularly randomized controlled trials, is essential to substantiate their antimicrobial effectiveness in specific diseases and types of wounds, considering their potential impact on clinical results.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.